The Value of Delayed 18F-FDG PET/CT Imaging for Differentiating Axillary Lymph Nodes in Breast Cancers
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Positron emission tomography/computed tomography (PET/CT) imaging with fluorodeoxyglucose (FDG) have been used as a powerful fusion modality in nuclear medicine not only for detecting cancer but also for staging and therapy monitoring. Nevertheless, there are various causes of FDG uptake in normal and/or benign tissues. The purpose of present study was to investigate whether additional delayed imaging can improve the diagnosis to differentiate the rates of FDG uptake at axillary lymph nodes (ALN) between malignant and benign in breast cancer patients. 180 PET/CT images were obtained for 27 patients with ALN uptake. The patients who had radiotherapy and chemotherapy were excluded from the study. 18F-FDG PET/CT scan at 50 min (early phase) and 90 min (delayed phase) after 18F-FDG injection were included in this retrospective study. The staging of cancers was confirmed by final clinical according to radiologic follow-up and pathologic findings. The standardized uptake value (SUV) of ALN was measured at the Syngo Acquisition Workplace by Siemens. The 27 patients included 18 malignant and 9 ALN benign groups and the 18 malignant groups were classified into the 3 groups according to number of metastatic ALN in each patient. ALNs were categorized less than or equal 3 as N1, between 4 to 9 as N2 and more than 10 as N3 group. Results are expressed as the mean ± standard deviation (S.D.) and statistically analyzed by SPSS. As a result, Retention index (RI-SUV max) in metastasis was significantly higher than that in non-metastasis about 5 fold increased. On the other hand, RI-SUV max in N group tended to decrease gradually from N1 to N3. However, we could not prove significance statistically in malignant group with ANOVA. As a consequence, RI-SUV max was good indicator for differentiating ALN positive group from node negative group in breast cancer patients. These results show that dual-time-point scan appears to be useful in distinguishing malignant from benign.
Abstract
Positron emission tomography/computed tomography (PET/CT) imaging with fluorodeoxyglucose (FDG) have been used as a powerful fusion modality in nuclear medicine not only for detecting cancer but also for staging and therapy monitoring. Nevertheless, there are various causes of FDG uptake in normal and/or benign tissues. The purpose of present study was to investigate whether additional delayed imaging can improve the diagnosis to differentiate the rates of FDG uptake at axillary lymph nodes (ALN) between malignant and benign in breast cancer patients. 180 PET/CT images were obtained for 27 patients with ALN uptake. The patients who had radiotherapy and chemotherapy were excluded from the study. 18F-FDG PET/CT scan at 50 min (early phase) and 90 min (delayed phase) after 18F-FDG injection were included in this retrospective study. The staging of cancers was confirmed by final clinical according to radiologic follow-up and pathologic findings. The standardized uptake value (SUV) of ALN was measured at the Syngo Acquisition Workplace by Siemens. The 27 patients included 18 malignant and 9 ALN benign groups and the 18 malignant groups were classified into the 3 groups according to number of metastatic ALN in each patient. ALNs were categorized less than or equal 3 as N1, between 4 to 9 as N2 and more than 10 as N3 group. Results are expressed as the mean ± standard deviation (S.D.) and statistically analyzed by SPSS. As a result, Retention index (RI-SUV max) in metastasis was significantly higher than that in non-metastasis about 5 fold increased. On the other hand, RI-SUV max in N group tended to decrease gradually from N1 to N3. However, we could not prove significance statistically in malignant group with ANOVA. As a consequence, RI-SUV max was good indicator for differentiating ALN positive group from node negative group in breast cancer patients. These results show that dual-time-point scan appears to be useful in distinguishing malignant from benign.
참고문헌 (9)
- Rigo P, "Oncological applications of positron emission tomography with fluorine-18 fluorodeoxy-glucose", Eur. J. Nucl. Med, 23(4), pp.1641~1674 (1996)
- Flier JS, "Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes", Science, 235(4795), pp.1492~1495 (1987)
- Monakhov NK, "Physicochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues", J. Natl. Cancer. Inst, 61(1), pp.27~34 (1978)
- Pauwels EK, "FDG accumulation and tumor biology", Nucl. Med. Biol, 25(4), pp.317~332 (1998)
- Higashi K, "Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma", J. Nucl. Med, 39(6), pp.1016~1020 (1998)
- Ichiya Y, "FDG-PET in infectious lesions: The detection and assessment of lesion activity", Ann. Nucl. Med., 10(2), pp.185~191 (1996)
- Clayton F, "Pathologic correlates of prognosis in lymph node-positive breast carcinomas", Cancer, 71(5), pp.1780~1790 (1993)
- Greco M, "Axillary lymph node staging in breast cancer by 2-fluoro- 2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management", J. Natl. Cancer Inst, 93(8), pp.630~635 (2001)
- Kumar R, "Potential of dual- time-point imaging to improve breast cancer diagnosis with 18F-FDG PET", J. Nucl. Med, 46(11), pp.1819~1824 (2005)